Catalent (CTLT) Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings or view top-rated stocks.

11 analysts have issued 1 year price targets for Catalent's stock. Their CTLT share price forecasts range from $28.00 to $145.00. On average, they anticipate the company's share price to reach $67.55 in the next year. This suggests a possible upside of 73.1% from the stock's current price.
View analysts price targets for CTLT or view top-rated stocks among Wall Street analysts.

Catalent's stock was trading at $45.01 at the start of the year. Since then, CTLT stock has decreased by 13.3% and is now trading at $39.01.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 28th 2023.
View our CTLT earnings forecast.

Catalent, Inc. (NYSE:CTLT) announced its quarterly earnings data on Monday, November, 1st. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.06. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. Catalent had a trailing twelve-month return on equity of 11.40% and a net margin of 8.62%. During the same period in the previous year, the company earned $0.33 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Catalent (NYSE:CTLT) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Alger 35 ETF (ATFV), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Dynamic Biotechnology & Genome ETF (PBE), SPDR S&P Pharmaceuticals ETF (XPH), First Trust Health Care AlphaDEX Fund (FXH), Harbor Health Care ETF (MEDI) and VanEck Pharmaceutical ETF (PPH).

Catalent issued an update on its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.25 billion-$4.35 billion, compared to the consensus revenue estimate of $4.44 billion.

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.95%), Artisan Partners Limited Partnership (4.30%), State Street Corp (4.00%), Veritas Asset Management LLP (3.82%), American Century Companies Inc. (2.44%) and Geode Capital Management LLC (2.07%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Manja Boerman, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph.
View institutional ownership trends.

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTLT stock can currently be purchased for approximately $39.01.

Catalent (NYSE:CTLT) has a market capitalization of $7.03 billion and generates $4.76 billion in revenue each year. The company earns $503 million in net income (profit) each year or $2.26 on an earnings per share basis.

The company employs 19,000 workers across the globe.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.